The National Neurofibromatosis Foundation (NNFF), Inc. held the 2003 meeting of the
“NNFF International Consortium for the Molecular Biology of Neurofibromatosis 1
and Neurofibromatosis 2” June 1-4, 2003 in Aspen CO.
Two Special Occasions Noted
The Foundation noted two special occasions at this meeting. First,
that the organization is celebrating its 25th Anniversary. NNFF President Peter
Bellermann thanked the Foundation’s co-founders Dr. Allan Rubenstein, Lynne
Courtemanche Shapiro R.N., and Joel Hirschtritt, Esq.—Dr. Rubenstein received
a standing ovation for his 25 years of dedicated service to the NNFF.
Second, the NNFF also celebrated the 10th Anniversary of the discovery of the gene for
Neurofibromatosis Type 2, in the laboratories of Dr. James Gusella
(MGH/Harvard), and Dr. Gilles Thomas (Fondation Jean Dausset, Paris) and Dr.
Guy Rouleau (McGill University, Montreal). All three were honorary co-chairs of
the first session, titled “Neurofibromatosis Type 2-Ten Years Later.”
Exceptional Progress During Past Year
Dr. David Gutmann (Washington University) and Dr. Marco Giovannini
(Fondation Jean Dausset, France) co-chaired the meeting.
Progress over the past year has been exceptional, and the audience was
energized by the information presented during the meeting. Mouse models
continue to provide a rich resource for experimental studies to understand the
biology of the NF1 and NF2 genes. The spirit of communication and
collaboration among NF researchers continues as use of these mouse models
expands to new laboratories and research fields. Cells and tissues from these
mice are a rich resource for studies in a number of laboratories trying to
understand the role of the NF1 or NF2 genes in normal and tumor cell function.
There were presentations this year on non-tumor features of NF1, including
cardiac and myeloid cell defects, bone abnormalities, and pain. Learning and
memory studies were presented for both mouse and fruit fly models. Microarray
technology is being used to identify the changes in gene expression in NF1 and
NF2 tissues, as a promising avenue toward identifying possible targets for
therapeutic development. Many scientists were overheard discussing new data,
possible collaborations, or projects that will be done on the return to the
laboratory.
Keynote Addresses
There were two keynote speakers at the meeting. Dr. Anton Berns (The
Netherlands Cancer Institute, Amsterdam) spoke about technologies that help to
dissect tumorigenesis in mouse models of cancer. These include the annotated
mouse genome sequence, the ability to manipulate the mouse germ line, efficient
genetic mapping strategies, high throughput mutagenesis screens, RNAi, in vivo
imaging technology, pathology analysis, CGH, and gene expression profiling. All
of these technologies contribute to the rapid expansion of our knowledge about
human tumors. In the mouse models, tumor samples can be used to identify
pathways involved in inhibition, maintenance, and progression of tumors. Tumors
can be monitored using fluorescent imaging technologies. Identified targets can
be identified and validated using current technologies, and suitable targets can
be entered into the process of drug design and development.
Dr. Mahendra Rao (NIA/NIH) spoke about neural stem cells, the potential to
use them for studying normal neural cell processes, and about the potential of
these cells as therapeutic agents in disease models.
Department of Defense and NIH Representatives Participating
The Department of Defense (DOD) and the National Institutes of Health (NIH)
were represented at this meeting as well. The DOD Neurofibromatosis Research
Program (NFRP) funds a large portion of NF research both nationally and
internationally, at a current rate of about $20 million per year. Dr. Rick Kenyon
(DOD) spoke about the NFRP and the latest call for applications. New this year
is the Clinical Trials Development Award, which will be a fast track process for
applicants for a year of funding to develop the resources necessary to propose a
clinical trial for DOD funding. He also announced the new policy for allowing for
resubmission of proposals, allowing for the first time a response to criticisms of
the previous review. He described the NF1 and NF2 story boards, a project that
the DOD has undertaken to present milestones and accomplishments in
research for NF, and invited comments and corrections from the participants of
the meeting. Dr. Robert Finkelstein (NINDS/NIH) was available for consultation
about possible funding through the NIH, and to describe new programs that
would provide funding opportunities for NF researchers.
NF2 Clinical and Research Findings
The first session was devoted to the accomplishments of NF2 clinical and
research findings. Dr. Mia MacCollin (MGH/Harvard) spoke about NF2
diagnostic criteria. Since 1987, four sets of diagnostic criteria have been
published, and while similar, they created the problem of not providing sufficient
information for the general clinician to make a diagnosis. The presence of
bilateral vestibular schwannomas (VS) is the standard criteria for diagnosis of
NF2. However, other symptoms may suggest NF2, in the absence of bilateral
tumors. Unilateral VS and the presence of a meningioma, schwannoma, or
glioma suggests NF2. Mosaicism is a common feature in NF2 founders
(nonfamilial patients), and complicates the diagnosis. Other features appear in
NF2 patients, but do not appear in the diagnostic criteria. Standard imaging
protocols do not meet the needs for diagnosing NF2, and specific protocols must
be described to screen presymptomatic cases. A separate, adjunct meeting was
held with a number of top NF2 clinicians, to discuss the NF2 diagnostic criteria
and make recommendations for the 2003 consensus on NF2 diagnostic criteria.
Dr. William Slattery (House Ear Institute) described the NF2 Natural History
Studies he is conducting with funding from the Department of Defense. The
primary purposes of the study were to develop an international consortium of
NF2 clinical centers, and to measure the growth rate and clinical course of the
disease. In addition, audiology measures were taken. To date, 103 patients
have been enrolled. Data have been collected that indicate that there is slow
growth over time, and that there is no correlation between right side vs. left side
in bilateral tumors. Growth rates are also not related to family history.
Audiological data indicate that hearing worsens over time, but newly diagnosed
cases have hearing stability for about 2 years. A follow-up study will use 3-D
volumetric analysis to detect growth in small tumors.
Dr. Vijaya Ramesh (MGH/Harvard) spoke of the functional significance of
NHERF/PDGF receptor binding in lamellipodia and membrane ruffles of cells.
Merlin, the NF2 protein, localizes to these structures. In cells which contained
mutant NHERF/PDGF interactions, the cytoskeletal elements did form. However,
there were spreading defects, reduced cell migration, and F-actin rearrangement
and increased focal adhesions. Dr. Andi McClatchey (MGH/Harvard) spoke
about signaling defects in NF2-deficient cells. In NF2-deficient cells, there was
loss of contact-dependent inhibition of growth, growth factor independence and
persistent growth factor receptor signaling, and aberrant differentiation. She also
presented data on the effect of the loss of ezrin in intestinal development. Loss
of ezrin resulted in high embryonic mortality, with only 16% of NF2 mouse
models surviving to birth. Of these, only one has survived to weaning. The
ezrin-deficient mice were found to have abnormal intestinal villi, with fusion of
microvilli at the brush border. She found that moesin expression in supporting
tissues sometimes moved into the surrounding villi in ezrin-deficient mice.
Dr. Marco Giovannini (Foundation Jean Dausset, France) presented information
about his NF2 mouse models. In conditional knock-out mice, expressing the crerecombinase
in Schwann cells, 90% of the mice developed Schwann cell
hyperplasia, and 40% developed schwannomas. Double mutant mice (with loss
of NF2 and NF1 genes) develop a spectrum of tumors related to both NF1 and
NF2 tumors. In addition, he showed that by exposing NF2 +/- mice to asbestos
fibers, he was able to model malignant mesothelioma, with inactivation of the WT
NF2 gene found in 85% of the mesotheliomas. An NF Mouse Models
Consortium Meeting was held in February hosting mouse neuropathologists and
NF animal models researchers, to develop a consensus on the classification of
the mouse peripheral nerve tumors. A paper will be submitted which describes
this group’s consensus.
Dr. Marcelo Curto (MGH/Harvard) spoke about NF2 conditional mice, crossed
with albumin-cre, for liver specific knock-out. In these mice after one month, the
livers are greatly enlarged, and there are oval cell tumors.
Dr. Richard Fehon (Duke University) spoke about the function of the ERM
proteins in Drosophila. The fruit fly has a gene related to the NF2 protein, termed
dmerlin, and only one gene related to the ERM proteins, referred to as dmoesin.
In addition, another gene has been shown to be part of the family, “the expanded
Drosophila gene”. Both dmerlin and dmoesin are expressed in all cells, although
merlin has punctate localization and moesin localizes to the apical microvillar and
adherens junctions. Both are required to establish anterior/posterior patterning.
Both merlin and moesin mutants have overproliferation of cells. Merlin interacts
with the “expanded protein” in a head-to-tail manner, suggesting partial
redundancy in function. Moesin does have a role in the Rho pathway, and
reducing the level of Rho reduces the moesin mutant phenotype.
Animal Models
Mouse models of NF1 and NF2 have become very important for understanding
not only tumor formation but also many of the other symptoms of the diseases.
Dr. Kevin Shannon (University of California, San Francisco) provided an update
on the NF Mouse Models Consortium, established to produce and characterize
models of NF1 and NF2, to identify biochemical pathways and targets, and to
provide the host for preclinical intervention studies. The Consortium continues to
interact with the NCI’s Mouse Models of Human Cancer Consortium, although it
is funded through the Department of Defense NF Research Program. There are
some hurdles that must be overcome in order for preclinical testing to move
ahead. There are also intellectual property concerns, among both
pharmaceutical and academic organizations. It is difficult to identify and obtain
lead compounds. At this point, preclinical testing in the laboratory is limited to
small numbers of animals, and does not yet involve high throughput testing.
Mouse model scientists in academic settings typically lack the necessary
expertise and resources. There will be an NF Mouse Models Consortium
Preclinical Therapeutics meeting in 2004 where a number of these issues will be
discussed. Participating will be academic scientists as well as biotech and
pharmaceutical experts.
Dr. Shannon spoke about his research involving mouse models of leukemia. By
using the NF1flox/flox mouse (created in the Parada lab) and crossing it with a
bone marrow-specific expressor of the cre-recombinase, he has been able to
demonstrate myeloproliferative disease in the mice by three months of age. He
is testing the GM-CSF inhibitor PD184352 in these mice. In JMML, patients have
GM-CSF hypersensitivity, although only 25% have activated Ras or NF1
mutations. In Noonan Syndrome, a genetic disease related to NF1, there are
reports of cases with JMML. There are mutations in the gene PTPN11 in 50% of
Noonan cases, and of patients with JMML without NF1 mutations or activated Ras,
80% have PTPN11 mutations.
Dr. David Gutmann (Washington University, St. Louis) described studies related
to astrocytoma modeling in the mouse. The NF1flox/flox mouse crossed to an
astrocyte-expressing cre mouse resulted in no tumor formation in the mice, even
after 20 months of age. This suggested that NF1 loss in astrocytes is not
equivalent to Ras activation. When NF1flox-astrocyte mice were crossed with a
lox-stop-lox Ki-Ras mouse, the NF1-deficient astrocytes had impaired cAMP
signaling. Crossing NF1flox-astrocyte mice with NF1 heterozygous mice resulted
in a swelling in the optic nerve and chiasm, reflecting more closely the NF1 optic
pathway glioma.
Dr. Karlyne Reilly (NCI/NIH) spoke about genetic modifiers in mouse
susceptibility to astrocytoma. In Nf1:p53 cis/C57Bl/6 mice, tumors arise with an
average latency of 7 months, and there is loss of p53 and increase in Ras
expression resulting from chromosome loss. When this mutation was crossed
into a 129S4/Sv strain, the mice were resistant to tumor formation, and small
tumors that did grow were very low grade. She plans to cross into other strain
backgrounds, and to identify strains with higher risk for astrocytoma or lower
occurrence of MPNST. With the proper genetic crosses, she will be able to
identify genes that act as modifiers of tumor expression.
Dr. Kristine Vogel (University of Texas, San Antonio) spoke about mutation
frequencies and tumor progression in NF1 and Nf1(+/-);Trp53(+/-) mouse
tissues. Mutations in NF1 or Trp53 affect the DNA repair mechanisms, resulting
in increased mutation frequency. Tumor cells lines have been generated, and
will be a valuable resource for testing a variety of DNA-damaging agents and
culture conditions for changes in the mutation frequency.
Dr. Kelly Monk (University of Cincinnati) described experiments designed to test
the relevance of the observation that there were EGFR(+) Schwann cells in
dermal and plexiform neurofibromas. In a transgenic mouse overexpressing
EGFR in Schwann cells, there were enlarged, fibrotic nerves, mast cell
accumulations, and disrupted axon-glial interactions, all features of human
neurofibromas. In a c-kit mutant with mast cell ablation, the nerve ultrastructure
could be restored. Dr. George Perrin (University of Florida) described a
xenograft mouse model of NF1 plexiform neurofibroma. Xenografts were
obtained by transplantation of MPNST cell lines into the nerves of Scid mice.
These tumors grew rapidly and reproducibly. He plans to use these mice to test
therapeutic agents.
Dr. Alcino Silva (University of California, Los Angeles) described studies on
learning and memory in NF1 mutant mice. He has demonstrated hyperactivation
of Mapk in NF1 mice. The NF1 mutation causes deficits in synaptic plasticity,
resulting in spatial learning deficits. Decreasing Ras function by genetic 7
manipulation or pharmacological intervention rescues these deficits. To
determine the location of the deficits, mice were engineered that had loss of NF1
expression specifically in excitatory neurons or in inhibitory neurons. Loss in
excitatory neurons resulted in no deficits, while loss of NF1 in both excitatory and
inhibitory neurons disrupted learning. Studies were done which showed that
increased GABA inhibition is not caused by post-synaptic changes in excitatory
neurons, and that NF1 regulates signaling around axonal terminals. Dr. Steven
Kushner (UCLA) described studies of Ras/Mapk signaling and the role in
cognition. Ras/Mapk acts presynaptically through Synapsin 1, and there is also
an increase in LTP in these mice.
Dr. Yuan Zhu (University of Texas, Southwestern Medical Center) spoke about
the use of conditional knock-out mice to study CNS tumors. Loss of p53 and
activation of the receptor tyrosine kinase pathway (RTK) occur during
astrocytoma formation. To answer the question of whether loss of NF1 and p53
is sufficient to induce astrocytoma, mice were generated with both p53 and NF1
mutations. Loss of only NF1 was not sufficient to cause astrocytoma formation.
Loss of both p53 and NF1, however, resulted in 100% astrocytoma formation. It
was also demonstrated that order was important, and that p53 loss must occur
first in order for tumors to form. It was also shown that the progenitor cells for
these tumors were neural stem cells.
Dr. Jon Epstein (University of Pennsylvania) spoke about the roles of NF1 and
Ras in cardiac development. The NF1flox/flox mouse was crossed with a mouse
expressing cre through the Tie-2 promoter, causing loss of NF1 expression in
endothelial cells. The resulting mice had heart and vascular defects, and can
serve as a model of the cardiovascular effects seen in patients with NF1.
Dr. Wade Clapp (Indiana University) described his studies on the role of mast
cells in NF1. Heterozygous NF1 (+/-) mice have increased numbers of peritoneal
and cutaneous mast cells. In other cancer models, inflammatory mast cells
upregulate angiogenesis, and mast cells localize to the tumor microenvironment.
In cell culture studies, embryonic day 13.5 Schwann cells from either wild type
(+/+) or double mutant NF1 (-/-) animals were mixed with heterozygous NF mast
cells. Conditioned media from the -/- mice caused increased migration of mast
cells, which was mediated through the a4-ß1 integrin.
Dr. Cynthia Hingtgen (Indiana University) is interested in understanding how
growth factors affect pain response (hyperalgesia) in NF1 patients, using NF1
(+/-) mice. There is increased Ras in these mice in response to growth factors.
Stem cell factor treated NF1(+/-) mice demonstrated mechanical hyperalgesia
compared to wild type (+/+) or untreated (+/-) animals. Central sensory neurons
also had a 3-4 fold increase in the release of neuropeptides substance P (SP)
and in calcitonin gene-related protein (CGRP) in response to capsaicin
stimulation. These neuropeptides are an indication of sensory neuron
sensitization and are important in initiation of the pain signal. Changes in levels
correlate with hyperalgesia. Further studies are needed in this area.
Dr. Janet Hock (Indiana University), a bone biologist and endocrinologist, is
studying the abnormalities in bone in NF1. Mouse models can be used to study
trabecular bone. There were no differences in bone between (+/+) and (+/-) mice
for bone mineral density, skull size, bone length, or trabecular bone
histomorphometry. There were differences in the biomechanical properties of
strength, and a decreased vertebral height. In NF1 (+/-) primary bone,
osteoclasts are hyperactivated, and there is an increase in p21Ras, Akt, and
apoptosis is enhanced in bone cells, although not in bone marrow stromal cells.
Dr. James Walker (MGH/Harvard) spoke about his work using Drosophila
microarrays to study changes in gene expression. He has identified 100 genes
that are downregulated greater than 2-fold, and 69 genes upregulated at least 2-
fold, and will study these genes to identify modifiers that may play a role in NF1
pathology. Dr. Yi Zhong (Cold Spring Harbor Laboratory) spoke about learning in
Drosophila. Overexpression of NF1 in flies results in an enhancement in
memory.
Molecular Genetics & Biology
Dr. Jan Friedman (University of British Columbia, Canada) spoke about the
natural history and risk factors for NF1. The course of NF1 is not predictable, as
symptoms vary widely among individuals, even within the same family. He
reported on studies that show that there is a correlation between certain features
of NF1 among families, including pigmentation, tumor burden, and risk for
malignancy. He described the data about a slightly increased risk for malignancy
and the shorter life expectancy for patients with NF1. These data, however, were
based on a set of patients who were followed at clinics which might see more of
the complicated cases of NF1.
Dr. Bruce Korf briefly described mutation analysis for NF1 germline and somatic
mutations. He also described the natural history study for plexiform
neurofibromas in NF1, funded by the DOD NFRP. The study "Natural History of
Plexiform Neurofibromas in NF1" is in its fourth year. The major goal of the study
is to use volumetric MRI to measure the growth rate of plexiform neurofibromas.
Although data are still being collected, and hence a final analysis has not been
done, we have begun to look at longitudinal growth data. The volumetric protocol
has been validated and produces volume data accurate to about 10%. We have
also identified imaging differences between superficial and deep plexiform
neurofibromas. Finally, it is hoped that the consortium of clinical data collection
centers will serve for future clinical studies, including clinical trials.
Dr. Margaret McLaughlin (MIT Center for Cancer Research) described her
studies on the hormonal regulation of neurofibroma growth. Hers is one of the
first studies of hormonal influences in neurofibromatosis, a phenomenon often
noted by patients with NF1. Estrogen receptors were not present on the tumor
cells. Progesterone receptors (PR), however, were found in 75% of the tumors.
The PR were found in every subtype of neurofibroma, but were not present in
schwannomas or MPNST. They were also not present in peripheral nerve.
There are two isoforms of PR, and both types were found in the tumors. Cells
that express PR could also express neurofibromin, but not S100. The PR+ cells
were either fibroblast or perineurial cells, not Schwann cells. Progesterone has
been shown to promote myelination in the CNS, and Schwann cells can produce
progesterone. These data suggest that the PR+ cells are non-neoplastic, but
may support the neoplastic cells. It is possible that anti-progestins, such as
RU486, may be therapeutic against these tumors.
Dr. Andre Bernards (MGH/Harvard) described a project looking for genetic
modifiers that might control the number or density of cutaneous neurofibromas in
NF1 patients. He is looking for patients with a very low or very high burden of
tumors, and will use genetic analyses to determine whether there are distinct
genes expressed (or not expressed) which lead to either of the tumor
phenotypes. Dr. Shyra Miller (University of Cincinnati) described experiments
using expression profile analysis to identify genes that are changed during
progression of neurofibromas into MPNST. From 8 cells lines, 6 NF1-related and
2 sporadic, she has identified a gene, p16/INK4 which is lost in NF1 associated
tumors. Dr. Karen Stephens (University of Washington) described her work on
NF1 microdeletions, in which 1.5 megabases are deleted in a region containing
the NF1 gene. She found that 70% of these microdeletions are recurrent and
occur at discrete recombination sites within the flanking repeat sequences
(NF1REP). Patients with this microdeletion genotype have a higher burden and
earlier appearance of cutaneous neurofibromas.
Dr. Jan Dumanski (Uppsala University, Sweden) described the use of high
resolution mapping to profile gene copy numbers in NF2-related samples using a
full-coverage chromosome 22 microarray. This array allows for accurate
detection of homozygous/heterozygous deletions, amplifications/gains, and
breakpoints of imbalanced translocations. This microarray may be useful in
detecting deletions in other genes, including the locus predisposing to
schwannomatosis, and future studies are focused on this study.
Dr. Karen Cichowski (BWH/Harvard) described studies on neurofibromin, which
is dynamically regulated by the proteosome. She is dissecting the signals that
contribute to neurofibromin stabilization or degradation. Neurofibromin is
degraded rapidly by the proteosome in response to growth factor stimulation, but
reappears shortly after growth factor treatment, playing a critical role in
terminating Ras signaling. Neurofibromin is phosphorylated as it is re-expressed,
and this phosphorylation is induced by expression of constitutively activated Ras,
Raf, and MEK, but not activated AKT. MEK inhibitors, but not PI3K inhibitors
block the phosphorylation. These data suggest a novel negative feedback model
where activation of the Ras/Raf/MEK pathway induced neurofibromin
phosphorylation, increasing its activity and stability.
Dr. Kelly Morgan (University of Minnesota) spoke about studies on a
myeloproliferative disorder associated with NF1. Data suggested that blocking of
the GM-CSF receptor or downstream signals may be of therapeutic benefit in
NF1-associated myeloid diseases. Reintroduction of the GRD domain of the
NF1 gene reduced the amount of activated K-Ras and N-Ras in myeloid cells,
however, the GRD was strongly selected against in the transduced cells, limiting
its use as a therapeutic agent. Inducible GRD and small interfering RNA against
GRD will be used to modulate the level of expression.
Dr. Michael Stern (Rice University) described studies concerning Ras regulation
of perineurial glial growth in Drosophila. Data indicated that Ras activity is
necessary and sufficient for increased perineurial glial growth, and that Ras can
promote this growth cell nonautonomously.
Dr. Eva Dombi (NCI/NIH) described the use of longitudinal automated volumetric
MRI analysis of plexiform neurofibromas as part of a Phase II clinical trial for
NF1. The trial is an ongoing double-blinded, placebo-controlled, cross-over
phase II trial using a farnesyltransferase inhibitor. At disease progression
(increase of tumor volume >20%), patients are crossed over to the second
phase. Automated volumetric MRI analysis reliably detects tumor progression
based on quantification of smaller changes in tumor size than can be detected by
either of the two standard tumor response criteria.
Dr. Westley Friesen (PTC Therapeutics) described the use of nonsense
suppression as a novel therapy for NF1 or NF2. More than 30% of NF1 patients,
and about 20% of NF2 patients have nonsense mutations. PTC is developing
compounds that allow for read-through of the nonsense mutation to produce
active, full length protein. Small molecules, such as gentamycin, have been
shown to read through nonsense mutations in Cystic Fibrosis, Hurlers Syndrome,
p53 and Duchenne Muscular Dystrophy. PTC is developing compounds that
function in a similar way, and will test them in preclinical studies to determine if
they are capable of restoring full-length neurofibromin and merlin to tumor cells.
Such compounds may provide therapeutic value to patients with NF1 or NF2.
Cell Biology
Dr. Michael Bennett (University of Cincinnati) spoke about the role of the NF1
gene in oligodendrocyte differentiation. He found that an NF1 mutation
increased the number of oligodendrocyte precursors, and that the precursors
showed increased Ras-GTP. This increase in cell number could be inhibited by
farnesyltransferase inhibitors.
Dr. Laurence Goutebroze (Fondation Jean Dausset, France) described the
association of CASPR/paranodin with merlin and ß1-integrin in the central
nervous system. This association is thought to be interdependent. Dr.
Dominique Lallemand (MGH/Harvard) spoke about the role of merlin in
tumorigenesis. NF2-deficient mouse embryo fibroblasts (MEF) do not undergo
contact-dependent inhibition of proliferation. He showed that NF2 MEF lack
“adherens junctions” and that if NF2 function is restored, “adherens junctions”
form and contact inhibition is restored.
Dr. Oliver Hanemann (University of Ulm, Germany) described the role of
Rac1/JNK signaling in schwannomas. In merlin-deficient schwannoma cells,
there is high Rac1 activity. This protein also phosphorylated merlin through PAK
activation. In primary human schwannoma cells, Rac1 and PAK are translocated
to the membrane, and there are increased levels of JNK in the nucleus. This
suggests that merlin regulates Rac1 activation, and downstream signaling, which
is important for schwannoma cell de-differentiation.
Dr. Nancy Ratner (University of Cincinnati) spoke about gene expression in NF1-
deficient Schwann cells. Schwann cells derived from NF1 null mice have
enhanced migration compared to wild type controls. Migration is not inhibited by
treatment with a farnesyltransferase inhibitor or a dominant negative H-Ras
adenovirus. However, two other Ras proteins, R-Ras and TC21, both affected
cell migration. Using a dominant negative R-Ras decreased migration 50%,
while TC21 activation increased migration 2-fold.
Dr. Feng-Chun Yang (Indiana University) discussed how loss of NF1 in Schwann
cells provides a stimulant for mast cell migration via the secretion of a Kit ligand.
The stimulus was potent for NF1+/- mast cells, but not for wild type cells. Using
protein arrays, candidate chemokines were identified. He showed that
hyperactivation of the Ras-Class1A-PI-3 kinase-Rac 2 pathway is directly
responsible for the increased migration of NF1+/- mast cells. |